Supply of Section 26 and Section 29 Medicines

Details

This Request For Information ("RFI") seeks to address the supply and management burden of subsidised Section 26 and Section 29 medicines on pharmacy, imposed though the additional legislative and administrative requirements which result in extra supply chain costs being passed on to pharmacy.
The solution should deliver a quality improvement approach aligned to the New Zealand Triple Aim. The three Triple Aim objectives, and the key outcomes that we want to achieve for each objective, are:
Improved quality, safety and experience of care
• Ensure that the relationship between community pharmacist and consumer is maintained.
• No new or additional costs to consumer or pharmacy.
Improved health and equity for all populations
• Deliver a nationally consistent service enabling timely dispensing and/or delivery of the prescribed medicine to all New Zealanders.
Best value for public health system resources
• Reduce wastage of medicines where stockholding occurs.
• Simplify administration/compliance costs of these medicines across the supply chain.
The potential solution we wish to evaluate under this RFI could involve DHBs collectively contracting for wholesale/distribution services for subsidised section 26/section 29 medicines for all DHB hospital pharmacies and community pharmacies including cost brand source and exceptional circumstances medicines.While we have indicated on GETS that the Price Band for the solution is $1M to $5M, this is an indicative Price Band only. The RFI process will inform the amount of funding that might be made available to implement a solution, if following this RFI a decision is made to issue a ROI or RFP for a solution. The amount of funding available for the solution sought may be different from the Price Band indicated.